Methoxetamine

Imbert et al. 2014 documented bradycardia and ST-elevation in a healthy 21-year-old after intranasal MXE. Patients with pre-existing cardiac conduction disorders face heightened risk of life-threatening arrhythmia.

Seizures documented in multiple MXE case reports in patients without epilepsy history. The compound lowers seizure threshold through NMDA antagonism-mediated cortical disinhibition. Absolute contraindication in patients with seizure disorders.

PPI disruption confirmed at all doses in rodent studies (Halberstadt et al. 2016). NMDA antagonists (ketamine, PCP) are well-established as psychotomimetics that can precipitate psychotic episodes. Absolute contraindication in patients with schizophrenia, schizoaffective disorder, or psychosis history.

CYP2B6 and CYP3A4 dependency confirmed by Meyer et al. 2013. Hepatic impairment would reduce metabolic clearance. The polydrug fatality case (Wiergowski 2014) included hepatic failure as part of multi-organ dysfunction. Relative contraindication — severity depends on degree of hepatic impairment.

Dargan et al. 2014 documented renal toxicity (tubular and glomerular damage) in mice after chronic MXE. Wiergowski et al. 2014 documented acute renal failure in a polydrug fatality. Pre-existing renal disease increases vulnerability.

No MXE-specific reproductive toxicity data exist. NMDA antagonist class (including ketamine) produces developmental neurotoxicity in animal models. Absolute contraindication based on class-level pharmacological mechanism and absence of any safety data.

SERT inhibition confirmed by Roth et al. 2013 (Ki = 479 nM). Any combination with drugs that increase synaptic serotonin (MAOIs being highest-risk, followed by SSRIs/SNRIs, tramadol, and MDMA) carries serotonin syndrome risk. No published MXE-specific serotonin syndrome case exists, but the pharmacological mechanism is established.

Bladder toxicity confirmed in mice (Dargan 2014) and rats (Wang 2017), with direct human urothelial cell toxicity in vitro. Patients with existing urological conditions face compounded damage. Particularly relevant for individuals with history of ketamine-associated uropathy.